Positive EU opinion for AstraZeneca’s Imfinzi

AstraZeneca and MedImmune have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending a marketing authorisation of Imfinzi (durvalumab) for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥1% of tumour cells and whose disease … Continue reading Positive EU opinion for AstraZeneca’s Imfinzi